Related Experiment Videos
Economic effects of beta-blocker therapy in patients with heart failure
Patricia A Cowper1, Elizabeth R DeLong, David J Whellan
1Outcomes Research and Assessment Group, Durham, North Carolina 27715, USA. cowpe001@mc.duke.edu
Insights
Beta-blocker therapy for heart failure improves survival and saves societal and Medicare costs. However, financial incentives for hospitals and physicians do not support increased use, necessitating policy changes.
Area of Science:
- Cardiology
- Health Economics
Background:
- Beta-blockers are recommended for heart failure (HF) patients.
- Current treatment rates are suboptimal, potentially due to economic factors.
- Understanding the economic impact is crucial for treatment adoption.
Purpose of the Study:
- To assess the economic effects of beta-blocker therapy in heart failure.
- To analyze costs and benefits from societal, Medicare, hospital, physician, and patient perspectives.
Main Methods:
- A 5-year Markov model simulated heart failure progression.
- Clinical trial data informed transition probabilities and beta-blocker effects on mortality and hospitalization.
- Hospital costs, reimbursement, and physician fees were estimated using real-world data.
Main Results:
- Beta-blocker therapy increased survival by 0.3 years per patient.
- Societal costs decreased by $3959 per patient; Medicare costs fell by $6064 per patient.
- Hospital and physician revenues decreased, while patient costs increased by $2113 over 5 years.
Conclusions:
- Beta-blocker therapy offers significant clinical and cost-saving benefits for society and Medicare.
- Current financial structures disincentivize hospitals and physicians from promoting beta-blocker use.
- Reimbursement reform and patient cost coverage are needed to encourage evidence-based practice patterns.
Purpose:
Studies suggest that beta-blockers improve outcomes in heart failure patients and may be cost saving to society. However, many heart failure patients are not treated with beta-blockers. Economic incentives facing hospitals, physicians, payers, and patients may not encourage treatment adoption. We assessed the economic effects of beta-blocker therapy from various perspectives: societal, Medicare, hospital, physician, and patient.
Methods:
A Markov model of heart failure progression over 5 years was developed. Transition probabilities and the effect of beta-blockers on mortality and hospitalization were based on clinical trial data. Estimates of hospital costs and reimbursement were obtained from the Duke University Medical Center. Physician fees were based on the Medicare fee schedule.
Results:
Beta-blocker therapy increased survival by 0.3 years per patient and reduced societal costs by US dollars 3959 per patient over 5 years. Medicare costs declined by US dollars 6064 per patient, due primarily to lower hospitalization rates. Unless heart failure admissions could be replaced with other hospitalizations that generated an equal or greater revenue above variable cost, hospital revenue would be negatively affected. Physician revenue from treating heart failure patients would also decline. Patient costs increased with beta-blocker use (US dollars 2113 over 5 years).
Conclusion:
Beta-blocker therapy improves the clinical outcomes of heart failure patients and is cost saving to society and Medicare. However, hospitals and physicians have no clear financial incentives to support increased beta-blocker use. Changes in practice patterns could be encouraged by linking reimbursement with evidence-based care and covering patients' medication costs.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:28Antihypertensive Drugs: Types of β-Blockers
01:17Antihypertensive Drugs: Action of β1 Blockers